Thirty-one biotechs raised $1.8 billion in follow-ons in 4Q, bringing the 2012 total to $6.3 billion. The 4Q12 money is more than twice the $698.3 million raised by 13 companies in 4Q11, and the full-year total is more than 50% higher than the $4.2 billion raised in 2011. Moreover, 13 follow-ons last year rasied $100 million or more. Four of them collected more than $200 million: Amylin Pharmaceuticals Inc., which was later acquired by Bristol-Myers Squibb Co. (NYSE:BMY), BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), Shanghai Fosun Pharmaceutical Group Co. Ltd. (Shanghai:600196; HKSE:2196) and Vivus Inc. (NASDAQ:VVUS).

4Q12 follow-ons and the 2012 follow-ons both are up a median of 1% since the deals. (A) Follow-ons of units consisting of stock and warrants are excluded from the post-money and percentage change calculations because the price per share was not available; (B) Totals for post-money and Dec. 31 market values exclude unit deals and acquired companies; (C) Median percentage change; $M; Source: BCIQ: BioCentury Online Intelligence

Company

Date

Raised

Post-$

12/31 mcap

% chg

Echo Therapeutics Inc. (NASDAQ:ECTE)

12/20/12

$3.5

$41.7

$45.6

9%

Galena Biopharma Inc. (NASDAQ:GALE) (A)

12/18/12

$24.3

NA

$126.7

NA

Cytori Therapeutics Inc. (NASDAQ:CYTX)

12/14/12

$20.0

$187.4

$184.1

-2%

Lpath Inc. (NASDAQ:LPTN)

12/14/12

$11.8

$64.5

$65.2

1%

Infinity Pharmaceuticals Inc. (NASDAQ:INFI)

12/13/12

$172.5

$1,212.0

$1,611.1

33%

Sarepta Therapeutics Inc. (NASDAQ:SRPT)

12/13/12

$125.0

$738.6

$754.7

2%

Arrowhead Research Corp. (NASDAQ:ARWR) (A)

12/7/12

$4.1

NA

$33.5

NA

Northwest Biotherapeutics Inc. (NASDAQ:NWBO)

12/7/12

$13.8

$103.8

$81.0

-22%

AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX)

12/6/12

$47.6

$122.5

$157.7

29%

Derma Sciences Inc. (NASDAQ:DSCI)

12/6/12

$36.4

$170.4

$183.1

7%

Durect Corp. (NASDAQ:DRRX)

12/6/12

$12.6

$91.5

$93.6

2%

NovaBay Pharmaceuticals Inc. (NYSE-M:NBY)

12/6/12

$7.4

$44.2

$40.3

-9%

Progenics Pharmaceuticals Inc. (NASDAQ:PGNX)

11/29/12

$25.3

$93.1

$138.7

49%

Rexahn Pharmaceuticals Inc. (NYSE-M:RNN) (A)

11/29/12

$6.6

NA

$35.8

NA

Supernus Pharmaceuticals Inc. (NASDAQ:SUPN)

11/29/12

$48.0

$243.7

$218.4

-10%

Venaxis Inc. (NASDAQ:APPY) (formerly AspenBio Pharma Inc.)

11/14/12

$4.7

$20.9

$25.5

22%

Array BioPharma Inc. (NASDAQ:ARRY)

11/9/12

$75.6

$421.9

$432.0

2%

Anacor Pharmaceuticals Inc. (NASDAQ:ARRY)

10/28/12

$24.0

$213.1

$185.0

-13%

Athersys Inc. (NASDAQ:ATHX)

10/26/12

$23.0

$52.8

$56.2

6%

Orexigen Therapeutics Inc. (NASDAQ:OREX)

10/25/12

$60.5

$434.2

$429.1

-1%

Xoma Corp. (NASDAQ:XOMA)

10/24/12

$40.0

$244.3

$195.7

-20%

Shanghai Fosun Pharmaceutical Group Co. Ltd. (Shanghai:600196; HKSE:2196)

10/23/12

$511.6

$3,410.4

$3,747.0

10%

Puma Biotechnology Inc. (NASDAQ:PBYI)

10/22/12

$138.0

$458.6

$537.5

17%

Cleveland BioLabs Inc. (NASDAQ:CBLI) (A)

10/19/12

$15.0

NA

$57.8

NA

ImmunoCellular Therapeutics Ltd. (NYSE-M:IMUC)

10/18/12

$21.0

$107.3

$98.1

-9%

Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX)

10/18/12

$39.4

$1,152.0

$1,132.3

-2%

MannKind Corp. (NASDAQ:MNKD) (A)

10/18/12

$80.0

NA

$567.7

1%

CytRx Corp. (NASDAQ:CYTR)

10/17/12

$23.0

$76.0

$56.9

-25%

Aeterna Zentaris Inc. (TSX:AEZ; NASDAQ:AEZS) (A)

10/12/12

$16.5

NA

$60.3

NA

Antares Pharma Inc. (NASDAQ:ATRS)

10/3/12

$50.0

$488.9

$476.8

-2%

Rigel Pharmaceuticals Inc. (NASDAQ:RIGL)

10/3/12

$130.0

$810.2

$565.5

-30%

4Q12 total (31 deals) (B)

$1,811.1

$11,004.2

$11,511.0

1% (C)

2012 total (111 deals) (B)

$6,321.7

$41,517.8

$44,123.0

1% (C)